Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma

Table 1 Patient Characteristics and Treatment Delivery

Patient	Age	Stage	Histology	Dose Level	XRT dose/Tx time (Gy/days)	Concurrent Pemetrexed Dose Received (mg/m ² )
1 TJ	55	IIIB	Ad	1	63/45	1150
2 ST	72	IIIB	Sq	1	63/48	900
3 LM	64	IIIA	Ad	1	39.6/33*	900
4 SR	45	IIIB	Ad	1	59.4/57	1200
5 MW	54	IV	Ad	1	63/47	1200
6 SR	75	IIIA	Ad	1	63/51	900
7 PH	68	IIIB	NOS	2/-1	63/55	1300
8 JD	72	IIIB	Ad	2/-1	63/51	1150
9 JB	78	IIIB	NOS	1A	63/47	900
10 BS	61	IV	NOS	1A	63/49	1200
11 ES	63	IV	Ad	1A	63/48	900
12 JB	83	IIIA	Sq	1A	63/53	1200
13 EH	73	IV	Ad	1A	63/54	1200
14 ML	74	IIIA	Ad	1A	63/47	1200
15 CN	74	IIIA	Sq	1A	63/49	1200
16 UG	62	IIIA	NOS	1A	63/48	1200

ISSN: 1748-717X